Verrica Pharmaceuticals earnings release, August 6, 2026

Verrica Pharmaceuticals Inc. (VRCA) · Form 8-K, Item 2.02 · Filed · SEC filing

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results – Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in

Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year – – Topline data from global Phase 3 program studying common warts currently expected in mid-2027 – – The Company’s cash runway could extend into 2028 based on its current operating plan and assuming full availability of its new credit facility – – Company reports total revenue of $5.9 million in Q2 2026, including U.S. YCANTH net product revenue of $5.1 million, up 18.7% over the previous quarter and 12.3% year-over-year – – Conference call scheduled for today, August 6, 2026, at 4:30 pm ET – WEST CHESTER, PA – Aug 6, 2026 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq:

VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced financial results for the second quarter ended June 30, 2026.

“Demand for YCANTH continues to accelerate, with dispensed applicator units reaching 19,626 for the quarter, up approximately 28% sequentially and 46% on a year-over-year basis, and representing our highest quarterly total since launch. We believe that our commercial strategy is working well and provides us with a growing confidence that YCANTH can become the standard of care for patients suffering from molluscum,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica.

“In addition to our commercial efforts, we also continue to make progress with our work to expand the label for YCANTH to include common warts, an indication that is more than three times the six million patients estimated to be suffering from molluscum. Topline data from our global Phase 3 program is currently expected in mid-2027, as our studies are recruiting well. We continue to enroll patients in the first pivotal study,

COVE-2, and first patients in the U.S. and Japan were dosed in the second pivotal trial,

COVE-3, during the quarter,” Dr. Rieger continued. “With respect to our basal cell carcinoma program, we remain highly encouraged by the Phase 2 data for our novel oncolytic peptide,

VP-315.

At the Society for Investigative Dermatology Annual Meeting in May,

VP-315 demonstrated a potential ability to impact both treated lesions, as well as showing evidence of a meaningful abscopal effect in untreated lesions. Based on the unique and promising profile of this Phase

3-ready asset, we are continuing our Phase 3 readiness activities.”

Dr. Rieger concluded, “Finally, our new credit facility for up to $27.5 million with an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder, gives us access to additional non-dilutive capital to support YCANTH’s continued commercialization and advance our ongoing Phase 3 common warts program. Based on our current operating plan, we believe the full $27.5 million that may be available under the facility could extend our cash runway into 2028. We believe this quarter’s progress across our

YCANTH business for molluscum and our pipeline programs, along with this extended cash runway, positions Verrica well to deliver long-term value for patients and shareholders.”

Conference Call and Webcast Information

The Company will host a conference call on Thursday, August 6, 2026, at 4:30 pm, to discuss its second quarter 2026 financial results and provide a business update. To participate in the conference call, please utilize the following information:

Domestic

Dial-In

Number: Toll-Free:

1-800-225-9448

International

Dial-In

Number:

1-203-518-9708

Conference ID: VERRICA

Participants can use Guest dial-in

#s above and be answered by an operator.

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1766684&tp_key=a08a369194

The call will be broadcast live over the Web and can also be accessed on Verrica Pharmaceuticals’ website: www.verrica.com.

The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.

Business Highlights and Recent Developments

YCANTH®

(VP-102)

VP-315

Corporate

Financial Results

Second Quarter 2026 Financial

Results

Year-to-date

Financial Results

Non-GAAP

Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP

(loss) income from operations, non-GAAP net (loss) income and non-GAAP net (loss) income per share. These non-GAAP financial measures exclude stock-based compensation expense and non-cash interest expense that are required by GAAP. Verrica excludes non-cash stock-based compensation expense from these non-GAAP measures to facilitate comparison to peer companies who also provide similar non-GAAP disclosures and because it reflects how management internally manages the business. In addition, Verrica excludes non-cash interest expense from these non-GAAP measures to facilitate an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies who also provide similar non-GAAP disclosures and because it is reflective of how management internally manages the business. Verrica also excludes certain other one-time expenses and impacts from change in fair value of derivative liability and legal settlement, net of insurance recovery.

Non-GAAP

(loss) income from operations, non-GAAP net (loss) income and non-GAAP net (loss) income per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results.

Non-GAAP...ss) income from operations, non-GAAP net (loss) income and non-GAAP net (loss) income per share have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.

About

YCANTH®

(VP-102)

YCANTH® is a proprietary drug-device combination product that contains a

GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of

YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. YCANTH is also approved for the treatment of molluscum contagiosum in Japan and is being studied in a global phase 3 program in the US and Japan for the treatment of common warts.

Approximately

250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.

About Verrica

Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH®

(VP-102)

(cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH®

(VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize

VP-315

(ruxotemitide, formerly known as

LTX-315 and

VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
RevenueProduct revenue, net5,0934,534
RevenueLicense and Collaboration revenue7698,168
RevenueTotal revenue5,86212,702
Operating Expenses:Cost of product revenue435340
Operating Expenses:Cost of collaboration revenue443154
Operating Expenses:Selling, general and administrative10,3498,852
Operating Expenses:Research and development6,0341,846
Operating Expenses:Legal settlement, net of insurance recovery1,698
Operating Expenses:Total expenses18,95911,192
Operating Expenses:(Loss) income from operations-13,0971,510
Operating Expenses:Interest income111228
Operating Expenses:Interest expense-164-2,131
Operating Expenses:Change in fair value of derivative liability598
Operating Expenses:Other expense-3-1
Operating Expenses:Net (loss) income-13,153204
Net (loss) income per shareBasic-0.620.02
Weighted average common shares outstandingBasic21,305,0259,488,055
Net (loss) income per shareDiluted-0.620.02
Weighted average common shares outstandingDiluted21,305,0259,490,600

Income Statement

Six Months Ended June 30, — (unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
RevenueProduct revenue, net9,3837,956
RevenueLicense and Collaboration revenue1,5028,185
RevenueTotal revenue10,88516,141
Operating Expenses:Cost of product revenue979763
Operating Expenses:Cost of collaboration revenue788168
Operating Expenses:Selling, general and administrative20,33817,700
Operating Expenses:Research and development9,8944,130
Operating Expenses:Legal settlement, net of insurance recovery1,698
Operating Expenses:Total expenses33,69722,761
Operating Expenses:Loss from operations-22,812-6,620
Operating Expenses:Interest income312565
Operating Expenses:Interest expense-324-4,334
Operating Expenses:Change in fair value of derivative liability852
Operating Expenses:Other expense-11-1
Operating Expenses:Net loss-22,835-9,538
Net loss per shareBasic and diluted-1.07-1.01
Weighted average common shares outstandingBasic and diluted21,305,0259,485,907

Income Statement

Three Months Ended June 30, 2025 — (in thousands, except share and per share data)

Three Months Ended June 30, 2025 – Income from OperationsThree Months Ended June 30, 2025 – Net incomeThree Months Ended June 30, 2025 – Net income per share
GAAP1,5102040.02
Non-GAAP Adjustments:Stock-based compensation - Selling, General & Admin (a)5885880.06
Non-GAAP Adjustments:Stock-based compensation - Research & Development (a)3003000.03
Non-GAAP Adjustments:Derivative liability change in value (b)-598-0.06
Non-GAAP Adjustments:Non-cash interest expense (b)6910.07
Non-GAAP Adjustments:Adjusted2,3981,1850.12

Income Statement

Six Months Ended June 30, 2025 — (in thousands, except share and per share data)

Six Months Ended June 30, 2025 – Loss from OperationsSix Months Ended June 30, 2025 – Net lossSix Months Ended June 30, 2025 – Net loss per share
GAAP-6,620-9,538-1.01
Non-GAAP Adjustments:Stock-based compensation - Selling, General & Admin (a)1,3731,3730.14
Non-GAAP Adjustments:Stock-based compensation - Research & Development (a)5415410.06
Non-GAAP Adjustments:Derivative liability change in value (b)-852-0.09
Non-GAAP Adjustments:Non-cash interest expense (b)1,3590.14
Non-GAAP Adjustments:Adjusted-4,706-7,117-0.75

Balance Sheet

June 30, 2026 — (unaudited) (in thousands)

June 30, 2026December 31, 2025
Cash11,19830,147
Accounts receivable11,0905,397
Deferred R&D services, current portion2,7181,958
Insurance recovery asset2,302
Inventory2,7122,236
Prepaid expenses and other assets2,6192,801
Total current assets32,63942,539
Deferred R&D services, non-current portion7062,354
PP&E, Lease right-of-use asset, other2,6722,238
Total assets36,01747,131
Legal settlement liability4,000
R&D funding liability8,4145,066
Other current and noncurrent liabilities19,29617,322
Total liabilities31,71022,388
Total stockholders’ equity4,30724,743
Total Liabilities & Stockholders’ Equity36,01747,131
Full release

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the

Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH, the clinical development and benefits of Verrica’s product candidates, including YCANTH

(VP-102) and

VP-315, the development and regulatory plans for YCANTH, the timing of release of clinical data from the Phase 3 studies of YCANTH for common warts, Verrica’s ability to borrow funds under the Facility, Verrica’s achievement of milestones set forth in the Facility, and the commercial performance of YCANTH in Israel. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, and other risks and uncertainties that are described in Verrica’s Annual Report on Form

10-K for the year ended December 31, 2025, Verrica’s Quarterly Report on Form

10-Q for the quarter ended June 30, 2026 to be filed with the SEC on August 6, 2026 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

VERRICA PHARMACEUTICALS INC.

Selected Statements of Operations Data

(in thousands except share and per share data)

(unaudited)

VERRICA PHARMACEUTICALS INC.

Selected Balance Sheets Data

(in thousands)

(unaudited)

VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands, except share and per share data)

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby

Interim Chief Financial Officer jkirby@verrica.com

Kevin Gardner

LifeSci Advisors kgardner@lifesciadvisors.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Verrica Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.